Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Abbott Laboratories (NYSE:ABT)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on March 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on February 10th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Thermon Group (NYSE:THR) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Federal Signal (NYSE:FSS) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Oracle (NYSE:ORCL) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Champion Homes (NYSE:SKY) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/20/2026.

Abbott Laboratories Stock Down 0.3%

Shares of ABT opened at $110.20 on Thursday. The stock has a fifty day simple moving average of $115.25 and a two-hundred day simple moving average of $124.19. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $191.50 billion, a PE ratio of 29.62, a price-to-earnings-growth ratio of 1.76 and a beta of 0.74. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the firm posted $1.34 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Analyst Ratings Changes

ABT has been the subject of several analyst reports. Oppenheimer dropped their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Royal Bank Of Canada lowered their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Citigroup reduced their target price on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, BTIG Research lowered their price target on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $136.16.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott launched year two of the “Abbott Dream Team” program with Real Madrid to engage U.S. youth and raise brand visibility for Abbott’s consumer/diagnostics businesses — a marketing move that can boost long‑term consumer awareness. Abbott and Real Madrid launch nationwide effort to build the next ‘Abbott Dream Team’
• Positive Sentiment: Coverage highlighting Abbott as a durable dividend name / “safer” dividend aristocrat supports income‑oriented investor demand and may underpin share support despite near‑term volatility. Hope for the Best and Plan for the Worst: The 5 Safest Dividend Aristocrats
• Positive Sentiment: Analyst writeups from Zacks highlight Abbott as both a long‑term value and growth stock based on style scores — these pieces can attract buy‑and‑hold investors and lift sentiment over time. Why Abbott (ABT) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Recent short‑term price coverage noted a bounce to roughly $112.65 on the last close, reflecting intra‑week volatility; this is informational but not a catalyst on its own. Abbott (ABT) Rises Higher Than Market: Key Facts
• Negative Sentiment: Citigroup trimmed its price target from $140 to $136 while maintaining a “buy” rating — a downgrade in upside potential that can blunt investor enthusiasm and weigh on the share price. Citigroup trims ABT price target (Benzinga)
• Negative Sentiment: Valuation and performance writeups point to a mixed share performance (YTD and 1‑year declines) and debate whether current pricing fully discounts Abbott’s growth risks — such narratives can trigger additional selling from momentum or quant strategies. Is Abbott Laboratories (ABT) Pricing Reflect Its Mixed Share Performance And Growth Prospects?

Insider Buying and Selling at Abbott Laboratories

In other news, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction on Wednesday, February 4th. The stock was bought at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president directly owned 24,628 shares in the company, valued at approximately $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Abbott Laboratories

A number of hedge funds have recently added to or reduced their stakes in ABT. Carr Financial Group Corp increased its position in shares of Abbott Laboratories by 2.0% during the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after acquiring an additional 76 shares during the period. Tortoise Investment Management LLC boosted its holdings in Abbott Laboratories by 10.7% in the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock valued at $108,000 after purchasing an additional 77 shares during the period. Gemmer Asset Management LLC grew its stake in Abbott Laboratories by 2.9% during the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after purchasing an additional 78 shares in the last quarter. Global Financial Private Client LLC increased its holdings in Abbott Laboratories by 3.3% during the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after purchasing an additional 79 shares during the period. Finally, Citizens & Northern Corp raised its position in Abbott Laboratories by 0.4% in the 3rd quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock valued at $2,930,000 after purchasing an additional 79 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.